title: [Study on patients with benign prostate hyperplasia treated by the therapeutic regimen of watchful waiting during a twenty-four-month follow-up period].
abstract: OBJECTIVE
  To analyze the changes of the main clinic parameters in patients with benign prostate hyperplasia (BPH) treated by watchful waiting and to find out the risk factors contributing the progress of BPH.
  
  
  METHODS
  According to the inclusion and exclusion criteria,61 patients diagnosed as BPH were recruited in the group of watchful waiting. Data on IPSS, prostate volume, prostate specific antigen (PSA), maximum flow rate, average flow rate and residual urine volume during follow-up period of 24 months, were recorded.
  
  
  RESULTS
  At 0, 12, 24 months, the IPSS, prostate volume (ml), PSA(ng/ml), maximum flow rate (ml/s) were 7 +/- 4, 4 +/- 3, 4 +/- 3; 33.0 +/- 9.0, 33.8 +/- 7.6, 30.9 +/- 6.8; 1.53 +/- 1.35, 1.43 +/- 0.95, 1.22 +/- 0.99; 17.1 +/- 5.0, 17.2 +/- 6.1, 19.2 +/- 8.0, respectively. At the end of the 24-months follow-up, all observed parameters had a little improvement except the average prostate volume in this group. Of the 61 patients, 42 (62%) progressed slowly or became better when comparing with baseline data of the study. Moreover, the difference between at 24-month and at baseline period, IPSS showed statistical significance (P < 0.0001) in t test. In the study of BPH progression risk factors by logistic regression analysis, prostate volume (P = 0.0910) and residual urine volume (P = 0.0780) showed a trend of becoming the risk factors.
  
  
  CONCLUSIONS
  Our study showed that patients treated with watchful waiting had slow progression and majority of these patients did not need to alter their treatment options. Through data analysis, we noticed that the changes of data watchful waiting patients could help us to choose more precise and reasonable treatment option in clinical practice.
authors.affiliation: Department of Urology, Beijing Hospital, Beijing 100730, China.
authors.forename: Yao-Guang
authors.initials: YG
authors.lastname: Zhang
authors.forename: Jian-Ye
authors.initials: JY
authors.lastname: Wang
authors.forename: Ming
authors.initials: M
authors.lastname: Liu
authors.forename: Jin
authors.initials: J
authors.lastname: Xu
authors.forename: Jian-Ye
authors.initials: JY
authors.lastname: Wu
authors.forename: Ying
authors.initials: Y
authors.lastname: Xin
authors.forename: Ben
authors.initials: B
authors.lastname: Wan
authors.forename: Dong
authors.initials: D
authors.lastname: Wei
authors.forename: Sheng-Cai
authors.initials: SC
authors.lastname: Zhu
authors.forename: Ping
authors.initials: P
authors.lastname: Zeng
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D002985:Clinical Protocols; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D011467:Prostate / Q000473:pathology; D017430:Prostate-Specific Antigen / Q000097:blood; D011470:Prostatic Hyperplasia / Q000188:drug therapy* / Q000473:pathology / Q000503:physiopathology; D014563:Urodynamics
chemical_list: D017430:Prostate-Specific Antigen